BIOTEST AG (BIO.DE) Fundamental Analysis & Valuation

FRA:BIO • DE0005227201

Current stock price

42.2 EUR
-0.4 (-0.94%)
Last:

This BIO.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BIO.DE Profitability Analysis

1.1 Basic Checks

  • BIO had negative earnings in the past year.
  • BIO had a positive operating cash flow in the past year.
  • In multiple years BIO reported negative net income over the last 5 years.
  • In multiple years BIO reported negative operating cash flow during the last 5 years.
BIO.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

  • The Return On Assets of BIO (-1.73%) is better than 66.67% of its industry peers.
  • BIO has a better Return On Equity (-4.81%) than 68.06% of its industry peers.
  • BIO has a better Return On Invested Capital (0.54%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO.DE Yearly ROA, ROE, ROICBIO.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

  • BIO's Operating Margin of 1.87% is fine compared to the rest of the industry. BIO outperforms 75.00% of its industry peers.
  • BIO's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 23.19%, BIO is in line with its industry, outperforming 51.39% of the companies in the same industry.
  • BIO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO.DE Yearly Profit, Operating, Gross MarginsBIO.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BIO.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
  • Compared to 1 year ago, BIO has about the same amount of shares outstanding.
  • BIO has about the same amout of shares outstanding than it did 5 years ago.
  • BIO has a better debt/assets ratio than last year.
BIO.DE Yearly Shares OutstandingBIO.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO.DE Yearly Total Debt VS Total AssetsBIO.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

  • An Altman-Z score of 2.36 indicates that BIO is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BIO (2.36) is better than 70.83% of its industry peers.
  • The Debt to FCF ratio of BIO is 46.44, which is on the high side as it means it would take BIO, 46.44 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 46.44, BIO is doing good in the industry, outperforming 76.39% of the companies in the same industry.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO has dependencies on debt financing.
  • BIO has a Debt to Equity ratio (1.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.36
ROIC/WACC0.09
WACC6.01%
BIO.DE Yearly LT Debt VS Equity VS FCFBIO.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 4.93 indicates that BIO has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 4.93, BIO belongs to the best of the industry, outperforming 81.94% of the companies in the same industry.
  • A Quick Ratio of 1.66 indicates that BIO should not have too much problems paying its short term obligations.
  • BIO has a Quick ratio (1.66) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO.DE Yearly Current Assets VS Current LiabilitesBIO.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BIO.DE Growth Analysis

3.1 Past

  • The earnings per share for BIO have decreased strongly by -117.24% in the last year.
  • Looking at the last year, BIO shows a very negative growth in Revenue. The Revenue has decreased by -15.85% in the last year.
  • BIO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO.DE Yearly Revenue VS EstimatesBIO.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO.DE Yearly EPS VS EstimatesBIO.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BIO. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 27.85, which means the current valuation is very expensive for BIO.
  • Based on the Price/Forward Earnings ratio, BIO is valued cheaper than 80.56% of the companies in the same industry.
  • BIO is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 27.85
BIO.DE Price Earnings VS Forward Price EarningsBIO.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BIO is valued a bit cheaper than 72.22% of the companies in the same industry.
  • 77.78% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 115.96
EV/EBITDA 43.06
BIO.DE Per share dataBIO.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. BIO.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.09%, BIO is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.64, BIO pays a better dividend. On top of this BIO pays more dividend than 90.28% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, BIO's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

  • On average, the dividend of BIO grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
BIO.DE Yearly Dividends per shareBIO.DE Yearly Dividends per shareYearly Dividends per share 2019 0 0 0 0 0

5.3 Sustainability

  • BIO's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO.DE Yearly Income VS Free CF VS DividendBIO.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO.DE Fundamentals: All Metrics, Ratios and Statistics

BIOTEST AG

FRA:BIO (6/6/2025, 7:00:00 PM)

42.2

-0.4 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.67B
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.85
P/S 2.63
P/FCF 115.96
P/OCF 115.96
P/B 3.28
P/tB 3.39
EV/EBITDA 43.06
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY3.59%
FCF(TTM)0.36
FCFY0.86%
OCF(TTM)0.36
OCFY0.86%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.36
F-Score3
WACC6.01%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A

BIOTEST AG / BIO.DE Fundamental Analysis FAQ

What is the fundamental rating for BIO stock?

ChartMill assigns a fundamental rating of 4 / 10 to BIO.DE.


Can you provide the valuation status for BIOTEST AG?

ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG (BIO.DE). This can be considered as Fairly Valued.


What is the profitability of BIO stock?

BIOTEST AG (BIO.DE) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for BIO stock?

The Earnings per Share (EPS) of BIOTEST AG (BIO.DE) is expected to grow by 1600% in the next year.